Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

Journal of Molecular Medicine

Volumn 79, Issue 5-6, 2001, Pages 243-253

  Hofbauer, Lorenz C ^a   Heufelder, Armin E ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Osteoclast; Osteoporosis; Osteoprotegerin; Receptor activator of NF B; Receptor activator of NF B ligand

Indexed keywords

ESTROGEN; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN SERINE THREONINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ALBERS SCHOENBERG DISEASE; BONE ATROPHY; BONE CELL; BONE METASTASIS; BONE TUMOR; CALCIFICATION; CELL ACTIVATION; CELL LINEAGE; CELL SURVIVAL; HUMAN; METABOLIC BONE DISEASE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PERIODONTAL DISEASE; REVIEW; RHEUMATIC DISEASE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; APOPTOSIS; BONE AND BONES; BONE DISEASES; CARRIER PROTEINS; CELL DIFFERENTIATION; GLYCOPROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0034937704     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090100226     Document Type: Review

References (138)

1. Advances in bone biology: The osteoclast
2. Regulation of osteoclast function
3. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis
4. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
5. Bone resorption by osteoclasts
6. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation
7. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
8. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells
9. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
10. Evidence for a role of a tumor necrosis factor-α (TNF-α) converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
11. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
12. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
13. Localization of RANKL (receptor activator of NF-κB ligand) mRNA and protein in skeletal and extraskeletal tissues
14. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene
15. Cloning and characterization of the gene encoding mouse osteoclast differentiation factor
16. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: Regulation of mRNA expression of osteoclast differentiation factor (ODF)
17. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
18. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures
19. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
20. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
21. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
22. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo
23. Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria
24. 2 cooperates with TRANCE in osteoclast induction from hematopoietic precursors: Synergistic activation of differentiation, cell spreading, and fusion
25. TGF-β enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF
26. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
27. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function
28. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
29. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells
30. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
31. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
32. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
33. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis
34. Expression of functional RANK on mature rat and human osteoclasts
35. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation
36. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-fms and receptor activator of nuclear factor κB (RANK) receptors
37. Sequential requirements for SCL/tal-1, GATA-2, macrophage colony-stimulating factor, and osteoclast differentiation factor/osteoprotegerin ligand in osteoclast development
38. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
39. RANK is essential for osteoclast and lymph node development
40. RANKing the importance of measles virus in Paget's disease
41. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif
42. Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase
43. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily
44. The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor
45. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src
46. Osteopetrosis in mice lacking NF-κB1 and NF-κB2
47. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling
48. TRAF6-deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling
49. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
50. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
51. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
52. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
53. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells
54. TR1, a new member of the tumor necrosis factor receptor family, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption
55. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
56. The osteoblast-specific transcription factor cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function
57. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
58. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts
59. Osteoclastogenesis-inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast
60. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone resorbing activity of isolated mature osteoclasts
61. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development
62. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
63. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin
64. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
65. The osteoblast: A sophisticated fibroblast under central surveillance
66. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation
67. Osteoblast maturation suppressed osteoclastogenesis in coculture with bone marrow cells
68. Fibroblastic stromal cells express receptor activator of NF-κB ligand and support osteoclast differentiation
69. Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow
70. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated
71. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
72. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis
73. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
74. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells
75. 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells
76. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells
77. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation
78. In vivo demonstration that parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene
79. The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK
80. Transforming growth factor-β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells
81. Basic fibroblast growth factor induces osteoclast formation by reciprocally regulating the production of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in mouse osteoblastic cells
82. 3 through suppressing the production of osteoclast differentiation factor
83. Activin A is an essential cofactor for osteoclast induction
84. Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells
85. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells
86. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
87. 3 or parathyroid hormone
88. Regulation of osteoprotegerin mRNA levels by prostaglandin in human bone marrow stroma E2 cells
89. Activation of peroxisome proliferator-activated receptor-γ pathway inhibits osteoclast differentiation
90. Indian hedgehog in the late-phase differentiation in mouse chondrogenic EC cells. ATDC5: Upregulation of type X collagen and osteoprotegerin ligand mRNAs
91. Role of ascorbic acid in the osteoclast formation: Induction of osteoclast differentiation factor with formation of the extracellular collagen matrix
92. Multilineage potential of adult human mesenchymal stem cells
93. Tumor necrosis factor-α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
94. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts
95. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells
96. Activation of osteoclasts by interleukin-1: Divergent responsiveness in osteoclasts formed in vivo and in vitro
97. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression
98. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges
99. The effect of a single dose of osteoprotegerin in postmenopausal women
100. Immunological characterization of circulating osteoprotegerin/osteo-clastogenesis inhibitory factor: Increased serum concentrations in postmenopausal women with osteoporosis
101. Osteoprotegerin serum levels in healthy volunteers
102. The relationship between circulating osteoprotegerin and estrogen in postmenopausal women
103. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women
104. Osteoprotegerin serum levels in men: Correlation with age, estrogen, and testosterone status
105. The role of osteoprotegerin and receptor activator of NF-κB ligand in the pathogenesis and treatment of rheumatoid arthritis
106. Activated T cells support osteoclast formation in vitro
107. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis
108. Arthritis patterns in rats with adjuvant-induced arthritis define distinct mechanisms of joint protection for IL-1ra, sTNF-RI, and OPG
109. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion
110. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
111. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
112. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
113. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent
114. 1:25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease
115. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone
116. 3 and RANKL
117. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells
118. Dental cells express factors that regulate bone resorption
119. Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells
120. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection
121. Gene expression of osteoprotegerin ligand, osteoprotegerin and receptor activator of NF-κB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation
122. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors
123. Human multiple myeloma cell lines express mRNA for osteoclast differentiation factor
124. New insights into role of microenvironment in multiple myeloma
125. Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro
126. Breast cancer cells interact with osteoblasts to support osteoclast formation
127. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor
128. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy
129. 3
130. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat
131. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
132. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord
133. Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells
134. Osteoprotegerin mitigates tail suspension-induced osteopenia
135. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis
136. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
137. 3-induced, NF-κB-dependent survival factor for endothelial cells
138. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development